Loading...
XWAR
MAB
Market cap37mUSD
Oct 27, Last price  
8.35PLN
1D
-0.48%
1Q
-13.38%
Jan 2017
-88.75%
IPO
-37.92%
Name

Mabion SA

Chart & Performance

D1W1MN
P/E
—
P/S
1.96
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.33%
Rev. gr., 5y
%
Revenues
69m
-54.50%
01,527,582985,375884,7845,800829,7002,733,0000000056,873,000163,982,000151,678,00069,019,000
Net income
-6m
L
0471,44900-3,891,200-4,461,200-4,597,000-55,826,000-57,887,000-68,870,000-64,708,000-57,188,0001,903,00023,192,00041,269,000-6,334,000
CFO
40m
P
0000-27,589,100-24,386,500-33,969,000-15,221,000-54,127,000-38,938,000-33,755,000-35,239,000-32,910,00038,839,000-2,333,00039,863,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Mabion S.A., a biotechnology company, engages in the development of various biotech drugs based on monoclonal antibody technology in Poland. The company develops, produces, and sells medicines for the treatment of neoplastic, autoimmune, metabolic, and neurological diseases. Its products include MabionCD20 and MabionHER2. The company was founded in 2007 and is based in Konstantynów Lódzki, Poland.
URL
https://www.mabion.eu/
IPO date
Aug 10, 2010
Employees
248
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT